Toward precision adjuvant immunotherapy in high-risk clear cell renal cell carcinoma: integrating plasma multiomics with PD-1 blockade
Abstract Despite curative-intent nephrectomy, approximately one-third of patients with localized clear cell renal cell carcinoma (ccRCC) eventually experience disease recurrence due to occult minimal residual disease. Although adjuvant immune checkpoint blockade has transformed postoperative management for patients at...